Is there a role for targeting vascular endothelial growth factor/receptor axis in the treatment of patients with metastatic melanoma?

Cancer

Volumn 119, Issue 3, 2013, Pages 477-480

  Kim, Kevin B ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; BEVACIZUMAB; CARBOPLATIN; DACARBAZINE; FIBROBLAST GROWTH FACTOR 2; INTERLEUKIN 2; INTERLEUKIN 8; IPILIMUMAB; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; RAF PROTEIN; SORAFENIB; TEMOZOLOMIDE; TUMOR MARKER; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ADVANCED CANCER; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CONTROL; CANCER GROWTH; CANCER IMMUNOTHERAPY; CELL DIFFERENTIATION; CELL MATURATION; COLORECTAL CANCER; DENDRITIC CELL; DISEASE ASSOCIATION; DRUG BINDING; DRUG CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERANCE; DRUG TOXICITY; DRUG WITHDRAWAL; FATIGUE; HUMAN; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; MELANOMA CELL; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OPEN STUDY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; STUDY DESIGN; TREATMENT RESPONSE; TUMOR REGRESSION; TUMOR RESISTANCE;

ALBUMINS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; MELANOMA; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; PACLITAXEL; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; SURVIVAL ANALYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84872944379     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27756     Document Type: Review

References (21)

1. Bedikian AY, Millward M, Pehamberger H, et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol. 2006; 24: 4738-4745.
2. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000; 18: 158-166.
3. Flaherty KT, Lee SJ, Schuchter LM, et al. Final results of E2603: a double-blind, randomized phase III trial comparing carboplatin (C)/paclitaxel (P) with or without sorafenib (S) in metastatic melanoma [abstract]. J Clin Oncol. 2010; 28 (suppl): Abstract 8511.
4. Hauschild A, Agarwala SS, Trefzer U, et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol. 2009; 27: 2823-2830.
5. Perez DG, Suman VJ, Fitch TR, et al. Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A. Cancer. 2009; 115: 119-127.
6. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005; 23: 7794-7803.
7. Hersh EM, O'Day SJ, Ribas A, et al. A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma. Cancer. 2010; 116: 155-163.
8. Kottschade LA, Suman VJ, Amatruda T 3rd, et al. A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group Study, N057E(1). Cancer. 2011; 117: 1704-1710.
9. Marneros AG,. Tumor angiogenesis in melanoma. Hematol Oncol Clin North Am. 2009; 23: 431-446, vii-viii.
10. Osada T, Chong G, Tansik R, et al. The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol Immunother. 2008; 57: 1115-1124.
11. Lev DC, Ruiz M, Mills L, McGary EC, Price JE, Bar-Eli M,. Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. Mol Cancer Ther. 2003; 2: 753-763.
12. Varker KA, Biber JE, Kefauver C, et al. A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann Surg Oncol. 2007; 14: 2367-2376.
13. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355: 2542-2550.
14. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007; 357: 2666-2676.
15. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008; 26: 2013-2019.
16. von Moos R, Seifert B, Simcock M, et al. Swiss Group for Clinical Cancer Research (SAKK). First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07). Ann Oncol. 2012; 23: 531-536.
17. Kim KB, Sosman JA, Fruehauf JP, et al. BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol. 2012; 30: 34-41.
18. Kottschade LA, Suman VJ, Perez DG, et al. A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group Study, N0775. Cancer. 2012; 118: 586-592.
19. Eisen T, Ahmad T, Flaherty KT, et al. Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis. Br J Cancer. 2006; 95: 581-586.
20. Fruehauf J, Lutzky J, McDermott D, et al. Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma. Clin Cancer Res. 2011; 17: 7462-7469.
21. Casanovas O, Hicklin DJ, Bergers G, Hanahan D,. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell. 2005; 8: 299-309.